Athira Pharma (ATHA)
(Delayed Data from NSDQ)
$1.92 USD
0.00 (0.00%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.92 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ATHA 1.92 0.00(0.00%)
Will ATHA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ATHA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ATHA
Is Stryker (SYK) Stock Outpacing Its Medical Peers This Year?
Is Arcutis Biotherapeutics (ARQT) Outperforming Other Medical Stocks This Year?
ATHA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Athira Pharma, Inc. (ATHA) is a Great Momentum Stock: Should You Buy?
All You Need to Know About Athira Pharma, Inc. (ATHA) Rating Upgrade to Buy
Down -24.75% in 4 Weeks, Here's Why You Should You Buy the Dip in Athira Pharma, Inc. (ATHA)
Other News for ATHA
Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
Athira Pharma appoints Javier San Martin as Chief Medical Officer
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
Athira Pharma announces publication of preclinical data on fosgonimeton
Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting